People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Daniel Drucker, the Canadian scientist renowned for discoveries that sparked the advent of Ozempic and other GLP-1 medicines ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in ...